# Pharmacokinetics and Safety of AmBisome and DKF-5122

> **NCT05749380** · PHASE1 · COMPLETED · sponsor: **Dongkook Pharmaceutical Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Invasive Fungal Infections
- Neutropenic Fever

## Interventions

- **DRUG:** AmBisome
- **DRUG:** DKF-5122

## Key facts

- **NCT ID:** NCT05749380
- **Lead sponsor:** Dongkook Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2022-01-28
- **Final completion:** 2022-01-28
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749380, "Pharmacokinetics and Safety of AmBisome and DKF-5122". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05749380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*